ALDX / Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q2 2022 Results - Earnings Call Transcript

Penny stocks are the wild west of the stock market. Fast-paced, unpredictable, and laden with potential treasures. more_horizontal

Stocks are up today as investors prepare for the latest information from the Federal Reserve concerning interest rates. The Federal Open Market Commit more_horizontal

Aldeyra Therapeutics (NASDAQ: ALDX ) stock is on the rise Wednesday after entering into an exclusive option agreement with AbbVie (NYSE: ABBV ). This more_horizontal

Shares of Aldeyra Therapeutics Inc. ALDX, -66.43% plummeted 61.9% toward a 3 1/2-year low in very active morning trading Monday, enough to pace the Na more_horizontal

Shares of Aldeyra Therapeutics (NASDAQ:ALDX) have lost two-thirds of their value Monday after the company warned the US Food and Drug Administration m more_horizontal

Aldeyra is a late-stage company developing therapies for immune-mediated diseases, with a focus on dry eye disease and allergic conjunctivitis. Their more_horizontal

Aldeyra Therapeutics reported $165 million in cash and cash equivalents as of March 31, 2023, with a net loss of $15.6 million for Q1 2023. The compan more_horizontal

Aldeyra (ALDX) soars on meeting primary and secondary endpoints in the late-stage study of reproxalap for patients with allergic conjunctivitis. more_horizontal